Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

被引：0

作者：

Sifat Sharmin

Mathilde Lefort

Johanna Balslev Andersen

Emmanuelle Leray

Dana Horakova

Eva Kubala Havrdova

Raed Alroughani

Guillermo Izquierdo

Serkan Ozakbas

Francesco Patti

Marco Onofrj

Alessandra Lugaresi

Murat Terzi

Pierre Grammond

Francois Grand’Maison

Bassem Yamout

Alexandre Prat

Marc Girard

Pierre Duquette

Cavit Boz

Maria Trojano

Pamela McCombe

Mark Slee

Jeannette Lechner-Scott

Recai Turkoglu

Patrizia Sola

Diana Ferraro

Franco Granella

Julie Prevost

Davide Maimone

Olga Skibina

Katherine Buzzard

Anneke Van der Walt

Bart Van Wijmeersch

Tunde Csepany

Daniele Spitaleri

Steve Vucic

Romain Casey

Marc Debouverie

Gilles Edan

Jonathan Ciron

Aurélie Ruet

Jérôme De Sèze

Elisabeth Maillart

Hélène Zephir

Pierre Labauge

Gilles Defer

Christine Lebrun-Frénay

Thibault Moreau

Eric Berger

机构：

[1] University of Melbourne,CORe, Department of Medicine

[2] Rennes University,The Danish Multiple Sclerosis Registry, Department of Neurology

[3] EHESP,Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine

[4] REPERES,Division of Neurology, Department of Medicine

[5] EA,Department of Medical and Surgical Sciences and Advanced Technologies

[6] Univ Rennes,Multiple Sclerosis Center

[7] CHU Rennes,Department of Neuroscience, Imaging, and Clinical Sciences

[8] Inserm,Dipartimento di Scienze Biomediche e Neuromotorie

[9] CIC 1414 (Centre d’Investigation Clinique de Rennes),Medical Faculty

[10] University of Copenhagen,Nehme and Therese Tohme Multiple Sclerosis Center

[11] Charles University in Prague and General University Hospital,Department of Basic Medical Sciences, Neuroscience and Sense Organs

[12] Amiri Hospital,College of Medicine and Public Health

[13] Hospital Universitario Virgen Macarena,School of Medicine and Public Health

[14] Dokuz Eylul University,Department of Neurology, John Hunter Hospital

[15] GF Ingrassia,Department of Neuroscience

[16] University of Catania,Department of Medicine and Surgery

[17] University G. d’Annunzio,Department of Emergency and General Medicine

[18] IRCCS Istituto delle Scienze Neurologiche di Bologna,Neurology Unit

[19] Università di Bologna,Department of Neuroscience

[20] 19 Mayis University,Department of Neurology

[21] CISSS Chaudière-Appalache,Central Clinical School

[22] Neuro Rive-Sud,Department of Neurology, Faculty of Medicine

[23] American University of Beirut Medical Center,Neurophysiology Department

[24] CHUM MS Center and Universite de Montreal,Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro

[25] KTU Medical Faculty Farabi Hospital,inflammation, Hôpital Neurologique Pierre Wertheimer

[26] University of Bari,Department of Neurology

[27] University of Queensland,Department of Neurology

[28] Royal Brisbane and Women’s Hospital,Neurocentre Magendie

[29] Flinders University,Department of Neurology

[30] University Newcastle,Département de neurologie

[31] Hunter New England Health,MS Unit

[32] Haydarpasa Numune Training and Research Hospital,Department of Neurology, CHU de Caen, MS Expert Centre

[33] Azienda Ospedaliera Universitaria,Department of Neurology

[34] University of Parma,Department of Neurology

[35] Parma University Hospital,Department of Neurology

[36] CSSS Saint-Jérôme,Department of Neurology

[37] Garibaldi Hospital,Department of Neurology

[38] Monash University,Department of Neurology

[39] The Alfred Hospital,Department of Neurology

[40] Monash University,Department of Neurology

[41] Rehabilitation and MS-Centre Overpelt and Hasselt University,Department of Neurology

[42] University of Debrecen,Department of Neurology

[43] Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino,Department of Neurology

[44] Westmead Hospital,Department of Neurology

[45] Université de Lyon,CRC SEP and Department of Neurology

[46] Université,Department of Neurology

[47] Hospices Civils de Lyon,Department of Neurology

[48] Observatoire Français de la Sclérose en Plaques,Department of Neurology

[49] Centre de Recherche en Neurosciences de Lyon,Department of Neurology

[50] INSERM 1028 et CNRS UMR 5292,Department of Neurology

来源：

CNS Drugs | 2021年 / 35卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1217 / 1232

页数：15

共 50 条

[41] Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia
Lasalvia, Pieralessandro
Hernandez, Fabian
Castaneda-Cardona, Camilo
Andres Cuestas, J.
Rosselli, Diego
VALUE IN HEALTH REGIONAL ISSUES, 2020, 23 : 13 - 18
[42] The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis
Kotov, S. V.
Fedorova, S. I.
Yakushina, T. I.
Lizhdvoy, V. Yu
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (02) : 74 - 78
[43] Effect of natalizumab on disease activity in relapsing-remitting multiple sclerosis patients
Agiela, Mabroka I. M.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
[44] Neurocognitive changes in patients with relapsing-remitting multiple sclerosis treated with natalizumab
Doehler, N.
Mueller, S.
Vehoff, J.
Galovic, M.
Tettenborn, B.
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 213 - 213
[45] Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
Alroughani, R.
Al Hashel, J.
Thussu, A.
Ahmed, S. F.
MEDICAL PRINCIPLES AND PRACTICE, 2013, 22 (05) : 495 - 499
[46] Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis
Goodin, Douglas
Jeffery, Douglas
Kappos, Ludwig
Lublin, Fred
Radue, Ernst-Wilhelm
Rammohan, Kottil
Reder, Anthony
Vollmer, Timothy
Agius, Mark
Stites, Tracy
Li, Bingbing
Cappiello, Linda
von Rosenstiel, Philipp
Calabresi, Peter
NEUROLOGY, 2013, 80
[47] Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis
Lorscheider, Johannes
Benkert, Pascal
Lienert, Carmen
Haenni, Peter
Derfuss, Tobias
Kuhle, Jens
Kappos, Ludwig
Yaldizli, Oezguer
JOURNAL OF NEUROLOGY, 2021, 268 (03) : 941 - 949
[48] Fingolimod versus glatiramer acetate in patients with relapsing-remitting multiple sclerosis - ASSESS study results
Cree, B. A.
Goldman, M. D.
Corboy, J. R.
Singer, B.
Fox, E.
Arnold, D. L.
Ford, C.
Weinstock-Guttman, B.
Bar-or, A.
Mientus, S.
Sienkiewicz, D.
Zhang, Y.
Karan, R.
Tenenbaum, N.
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 163 - 163
[49] Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis
Fakih, Ali Ussama
Sahraian, Mohammad Ali
Paybast, Sepideh
Moghadasi, Abdorreza Naser
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 71
[50] Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia
Algahtani, Hussein
Shirah, Bader
Al Malik, Yaser
Meftah, Ibraheem
CLINICAL NEUROPHARMACOLOGY, 2020, 43 (02) : 35 - 38

← 1 2 3 4 5 →